Vascular dimorphism ensured by regulated proteoglycan dynamics favors rapid umbilical artery closure at birth.
Ontology highlight
ABSTRACT:
SUBMITTER: Nandadasa S
PROVIDER: S-EPMC7529456 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
Publications
Vascular dimorphism ensured by regulated proteoglycan dynamics favors rapid umbilical artery closure at birth.
Nandadasa Sumeda S Szafron Jason M JM Pathak Vai V Murtada Sae-Il SI Kraft Caroline M CM O'Donnell Anna A Norvik Christian C Hughes Clare C Caterson Bruce B Domowicz Miriam S MS Schwartz Nancy B NB Tran-Lundmark Karin K Veigl Martina M Sedwick David D Philipson Elliot H EH Humphrey Jay D JD Apte Suneel S SS
eLife 20200910
The umbilical artery lumen closes rapidly at birth, preventing neonatal blood loss, whereas the umbilical vein remains patent longer. Here, analysis of umbilical cords from humans and other mammals identified differential arterial-venous proteoglycan dynamics as a determinant of these contrasting vascular responses. The umbilical artery, but not the vein, has an inner layer enriched in the hydrated proteoglycan aggrecan, external to which lie contraction-primed smooth muscle cells (SMC). At birt ...[more]
Similar Datasets
Project description:The wound healing response is one of most primitive and conserved physiological responses in the animal kingdom, as restoring tissue integrity/homeostasis can be the difference between life and death. Wound healing in mammals is mediated by immune cells and inflammatory signaling molecules that regulate tissue resident cells, including local progenitor cells, to mediate closure of the wound through formation of a scar. Proteoglycan 4 (PRG4), a protein found throughout the animal kingdom from fish to elephants, is best known as a glycoprotein that reduces friction between articulating surfaces (e.g. cartilage). Previously, PRG4 was also shown to regulate the inflammatory and fibrotic response. Based on this, we asked whether PRG4 plays a role in the wound healing response. Using an ear wound model, topical application of exogenous recombinant human (rh)PRG4 hastened wound closure and enhanced tissue regeneration. Our results also suggest that rhPRG4 may impact the fibrotic response, angiogenesis/blood flow to the injury site, macrophage inflammatory dynamics, recruitment of immune and increased proliferation of adult mesenchymal progenitor cells (MPCs) and promoting chondrogenic differentiation of MPCs to form the auricular cartilage scaffold of the injured ear. These results suggest that PRG4 has the potential to suppress scar formation while enhancing connective tissue regeneration post-injury by modulating aspects of each wound healing stage (blood clotting, inflammation, tissue generation and tissue remodeling). Therefore, we propose that rhPRG4 may represent a potential therapy to mitigate scar and improve wound healing.
| S-EPMC9232611 | biostudies-literature
Project description:Decellularized vascular grafts are useful for the construction of biological small-diameter tissue-engineered vascular grafts (≤6 mm). Traditional chemical decellularization requires a long treatment time, which may damage the structure and alter the mechanical properties. Decellularization using sonication is expected to solve this problem. The aim of this study was to develop an effective decellularization method using ultrasound followed by washing. Different power values of sonication at 40 kHz were tested for 2, 4, and 8 h followed by a washing procedure. The efficacy of sonication of decellularized human umbilical artery (sDHUA) was evaluated via DNA content, histological staining, mechanical properties, and biocompatibility. The sDHUAs were further implanted into rats for up to 90 days and magnetic resonance angiography (MRA) was performed for the implanted grafts. The results demonstrated that treatment of human umbilical artery (HUA) by sonication at ultrasonic power of 204 W for 4 h followed by washing for 24 h in 2% SDS buffer could eliminate more than 90% of cells and retain similar mechanical properties of the HUA. Recellularization was assessed by scanning electron microscopy (SEM), which indicated that sDHUA provided niches for human umbilical vein endothelial cells (HUVECs) to reside, indicating in vitro cytocompatibility. Further implantation tests also indicated the fitness of the sonication-treated HUA as a scaffold for small-caliber tissue engineering vascular grafts.
| S-EPMC8196986 | biostudies-literature
Project description:The gold standard vascular substitutes, used in cardiovascular surgery, are the Dacron or expanded polytetrafluoroethylene (ePTFE)-derived grafts. However, major adverse reactions accompany their use. For this purpose, decellularized human umbilical arteries (hUAs) may be proven as a significant source for the development of small diameter conduits. The aim of this study was the evaluation of a decellularization protocol in hUAs. To study the effect of the decellularization to the hUAs, histological analysis was performed. Then, native and decellularized hUAs were biochemically and biomechanically evaluated. Finally, broad proteomic analysis was applied. Histological analysis revealed the successful decellularization of the hUAs. Furthermore, a great amount of DNA was removed from the decellularized hUAs. Biomechanical analysis revealed statistically significant differences in longitudinal direction only in maximum stress (p < 0.013) and strain (p < 0.001). On the contrary, all parameters tested for circumferential direction exhibited significant differences (p < 0.05). Proteomic analysis showed the preservation of the extracellular matrix and cytoskeletal proteins in both groups. Proteomic data are available via ProteomeXchange with identifier PXD020187. The above results indicated that hUAs were efficiently decellularized. The tissue function properties of these conduits were well retained, making them ideal candidates for the development of small diameter vascular grafts.
| S-EPMC7460081 | biostudies-literature
Project description:Currently the use of tissue engineered small diameter vascular grafts (d< 6 mm) as substitutes in vascular reconstruction has gained significant attention by the cardiovascular surgeons. Cardiovascular disease (CVD) is among the leading causes of death, worldwide. It is estimated that more than 17 million people have been diagnosed with CVD. As vascular substitutes autologous vessels such as saphenous vein, radial and mammary arteries, are currently used. Although that these vessels are used in an autologous manner, avoiding thrombus formation and immune rejection, suitable grafts can be found in less than 40% of the patients. During the last years, synthetic polymer grafts derived either from Dacron or expanded tetrafluoroethylene (ePTFE) have been developed and applied in vascular bypass surgeries. These grafts also have received FDA approval for their use in CVD. As large diameter vascular grafts (d > 6 mm), the synthetic conduits have shown promising results. On the other hand, significant adverse reactions have been reported, when are used as small diameter vascular grafts (SDVGs, d< 6 mm). The most important adverse reaction is the low patency rate that is observed, within the first year of implantation (< 70%). The lack of the endothelium layer makes these grafts susceptible to platelets aggregation and thrombus formation. Also, mismatch compliance could result to intima hyperplasia, activation of Th1/ Th2 response, calcification and overall graft failure. Taking into consideration the above data, alternative sources of SDVGs must be established. In this way, the human umbilical arteries (hUAs) may represent significant candidates for SDVGs development. HUAs, are muscular arteries, responsible for transportation of non-oxygenated blood from the fetus to mother. Their inner diameter is approximately 2-4 mm, while their length can be varied and it is dependent to the length of the human umbilical cord (hUC) . The length of a typical hUC is 30- 60 cm. HUAs can be isolated non-invasively from the hUC, a material which is discarded after the gestation. These muscular arteries are characterized by three distinct layers, tunica intima, media and adventitia, where specific cellular populations such as endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are located. Decellularization approach, a tissue engineering method, can be applied in hUAs, in order acellular non-imunogenic SDVGs to be developed. Decellularization approach uses a combination of physical, chemical and enzymatic methods, to remove the cellular populations, while at the same time preserve the extracellular matrix (ECM) and tissue’s ultrastructure. Then, these vascular conduits can be repopulated with recipient’s ECs and VSMCs, in order to be fully compatible and functional. The aim of the current project is mainly focused to the proteomic identification and characterization of hUAs, before and after the application of the decellularization approach. The preservation of the ECM proteins like collagen, fibronectin, laminin in the decellularized hUAs, are of major importance for their key mechanical and functional properties. Until date, only a few studies have performed a broad proteomic approach in decellularized SDVGs such as the hUAs. Also, the proteomic data will be compared with the histological, biochemical and biomechanical analysis results. For this project, the hUAs were isolated from the delivered human umbilical cords to Hellenic Cord Blood Bank (HCBB) of Biomedical Research Foundation Academy of Athens (BRFAA). Human umbilical cords were obtained from end term gestations (38-40 weeks), either with normal or caesarian delivery. Each hUC was accompanied by signed informed consent by the mother before the gestation. The informed consent was in accordance with the Helsinki declaration and fulfilled the ethical standards of the Greek National Ethical Committee. After the isolation of hUAs, the decellularization approach was performed. Specifically, the hUAs were incubated in decellularization buffer 1 (DB1), consisted of 8 mM CHAPS, 1 M NaCl and 25 mM EDTA in PBS 1x, for 12 hours (h) at room temperature (RT). Briefly washes of hUAs for removal of the excess of DB1 with PBS 1x, was performed. Then, the hUAs were placed in DB2, consisted of 1.8 mM SDS, 1 M NaCl and 25 mM EDTA in PBS 1x for another 12 h at RT, followed by briefly washes with PBS 1x. Finally, the hUAs were incubated at 37o C for 12 h in α-Μinimum Essentials Medium (α-ΜΕΜ) with 40% v/v Fetal Bovine Serum (FBS), ensuring the complete removal of genetic material remnants. To evaluate the impact of the current decellularization protocol in hUAs, histological analysis, biochemically, biomechanically evaluation and full spectrum proteomic analysis were performed.
2020-08-10 | PXD020187 | Pride
Project description:Small diameter (<6 mm) vessel grafts still pose a challenge for scientists worldwide. Decellularised umbilical artery (dUA) remains promising as small diameter tissue engineered vascular graft (TEVG), yet their immunogenicity remains unknown. Herein, we evaluated the host immune responses, with a focus on the innate part, towards human dUA implantation in mice, and confirmed our findings in an ex vivo allogeneic human setup. Overall, we did not observe any differences in the number of circulating white blood cells nor the number of monocytes among three groups of mice (1) dUA patch; (2) Sham; and (3) Mock throughout the study (day -7 to 28). Likewise, we found no difference in systemic inflammatory and anti-inflammatory cytokine levels between groups. However, a massive local remodelling response with M2 macrophages were observed in the dUA at day 28, whereas M1 macrophages were less frequent. Moreover, human monocytes from allogeneic individuals were differentiated into macrophages and exposed to lyophilised dUA to maximize an eventual M1 response. Yet, dUA did not elicit any immediate M1 response as determined by the absence of CCR7 and CXCL10. Together this suggests that human dUA elicits a minimal pro-inflammatory response further supporting its use as a TEVG in an allogeneic setup.
| S-EPMC8347020 | biostudies-literature
Project description:Six cases of full spontaneous closure of congenital coronary artery fistulas, and one case of near closure, as seen by colour Doppler echocardiography, are presented. It is worth reconsidering the classical view that nearly all cases of spontaneous closure are eligible for surgical or percutaneous correction to prevent the development of significant and potentially fatal complications. As the natural course of coronary artery fistulas is still poorly defined, asymptomatic patients, especially those under 7 years old with small shunts, should be periodically followed up by echocardiography rather than be subjected to operative closure, even by catheterisation.
| S-EPMC1729705 | biostudies-literature
Project description:BackgroundThe aims of this study were to evaluate the time intervals of flow velocity waveforms (FVW) of ductus venosus (DV) and cardiac cycles, as well as the pulsatility index of DV-FVW (DV-PI), in correlation with umbilical artery (UA) pH at birth in fetal growth restriction (FGR) complicated with placental insufficiency.MethodsData were retrospectively retrieved from pregnancies complicated by FGR. FGR was defined as an estimated fetal weight below - 2.0 S.D. with an elevated UA-PI. Time interval assessments of DV-FVW were as follows: the duration of systolic wave was divided by the duration of diastolic wave and defined as DV-S/D. We also measured the following time intervals of ventricular inflow through tricuspid valve (TV) and mitral valve (MV): (iii), from the second peak of ventricular inflow caused by atrial contraction (A-wave) to the opening of atrio-ventricular valves and: (iv), from the opening of atrio-ventricular valves to the peak of A-wave. (iii)/(iv) was expressed as TV-S/D and MV-S/D, for TV and MV, respectively. The time interval data were transformed into z-scores.ResultsThirty-one FGR fetuses were included in this study. Both DV-PI and DV-S/D showed significant correlation with UA-pH (r = - 0.677, p = < 0.001 and r = 0.489, p = 0.005 for DV-PI and z-score of DV-S/D, respectively) and more significances were observed in FGR ≤ 28 + 6 gestational weeks (r = - 0.819, p < 0.001 and r = 0.726, p = 0.005, for DV-PI and z-score of DV-S/D, respectively) than in FGR > 28 + 6 gestational weeks (r = - 0.634, p = 0.007 and r = 0.635, p = 0.020, for DV-PI and z-score of DV-S/D, respectively). On the other hand, TV-S/D and MV-S/D showed no significant correlation with UA-pH, although these z-scores indicated significant decreases compared with normal references.ConclusionsTime interval analysis of DV-FVW might be a valuable parameter, as well as DV-PI, for the antenatal prediction of fetal acidemia in the management of FGR fetuses.
| S-EPMC8489040 | biostudies-literature
Project description:Lumican is an extracellular matrix glycoprotein widely distributed in mammalian connective tissues. Corneal lumican modified with keratan sulfate constitutes one of the major proteoglycans of the stroma. Lumican-null mice exhibit altered collagen fibril organization and loss of corneal transparency. A closely related protein, keratocan, carries the remaining keratan sulfate of the cornea, but keratocan-null mice exhibit a less severe corneal phenotype. In the current study, we examined the effect of lumican overexpression in corneas of wild type mice. These mice showed no alteration in collagen organization or transparency but had increased keratocan expression at both protein and mRNA levels. Corneas of lumican-null mice showed decreased keratocan. This coupling of keratocan expression with lumican also was observed after intrastromal injection of a lumican expression minigene into the corneal stroma of Lum-/- mice. Small interfering RNA knockdown of lumican in vitro reduced keratocan expression, whereas co-injection of a lumican-expressing minigene with a beta-galactosidase reporter driven by the keratocan promoter demonstrated an increase of keratocan transcriptional activity in response to lumican expression in Lum-/- corneas in vivo. These observations demonstrate that lumican has a novel regulatory role in keratocan expression at the transcriptional level. Such results help provide an explanation for the differences in severity of corneal manifestation found in Lum-/- and Kera-/- mice. The results also suggest a critical level of small proteoglycans to be essential for collagen organization but that overabundance is not detrimental to extracellular matrix morphogenesis.
| S-EPMC2874675 | biostudies-literature
Project description:The goal of this study was to assess the frequency and predictors of vascular closure device (VCD) deployment failure, and its association with vascular complications of 3 commonly used VCDs.VCDs are commonly used following percutaneous coronary intervention on the basis of studies demonstrating reduced time to ambulation, increased patient comfort, and possible reduction in vascular complications as compared with manual compression. However, limited data are available on the frequency and predictors of VCD failure, and the association of deployment failure with vascular complications.From a de-identified dataset provided by Massachusetts Department of Health, 23,813 consecutive interventional coronary procedures that used either a collagen plug-based (n = 18,533), a nitinol clip-based (n = 2,284), or a suture-based (n = 2,996) VCD between June 2005 and December 2007 were identified. The authors defined VCD failure as unsuccessful deployment or failure to achieve immediate access site hemostasis.Among 23,813 procedures, the VCD failed in 781 (3.3%) procedures (2.1% of collagen plug-based, 6.1% of suture-based, 9.5% of nitinol clip-based VCDs). Patients with VCD failure had an excess risk of "any" (7.7% vs. 2.8%; p < 0.001), major (3.3% vs. 0.8%; p < 0.001), or minor (5.8% vs. 2.1%; p < 0.001) vascular complications compared with successful VCD deployment. In a propensity score-adjusted analysis, when compared with collagen plug-based VCD (reference odds ratio [OR] = 1.0), nitinol clip-based VCD had 2-fold increased risk (OR: 2.0, 95% confidence interval [CI]: 1.8 to 2.3, p < 0.001) and suture-based VCD had 1.25-fold increased risk (OR: 1.25, 95% CI: 1.2 to 1.3, p < 0.001) for VCD failure. VCD failure was a significant predictor of subsequent vascular complications for both collagen plug-based VCD and nitinol clip-based VCD, but not for suture-based VCD.VCD failure rates vary depending upon the type of VCD used and are associated with significantly higher vascular complications as compared with deployment successes.
| S-EPMC3427601 | biostudies-literature
Project description:Patients who are candidates to receive an Angioseal® (St. Jude Medical) device for arteriotomy closure are allowed to ambulate 20 min after the deployment of the device. More frequently, however, patients are kept on bed rest for several hours following Angioseal® deployment. The purpose of this study was to prospectively assess patients when ambulating 20 min after Angioseal® deployment instead of prolonged best rest of 2-3 h.Patients undergoing angiography from the common femoral artery approach were included in the study if they received a 6 Fr Angioseal® closure device.Twenty-nine patients were successfully enrolled in the study; 27 (93.1%) patients ambulated at 20 min, 1 (3.45%) patient ambulated at 28 min, and 1 (3.45%) patient ambulated at 27 min due to transport times. There were zero complications with regard to hemorrhage or other groin complications. There is a substantial time difference in ambulation times between the conventional and early ambulation groups.Our study demonstrates that it is probably safe to ambulate patients who undergo diagnostic cardiac catheterization as early as 20 min after deployment of the 6 Fr Angioseal® closure device. ClinicalTrials.gov identifier: NCT03142126.
| S-EPMC5941674 | biostudies-literature